NEO-POLYCIN HC Rx
Generic Name and Formulations:
Neomycin (as sulfate) 3.5mg, polymyxin B sulfate 10000 Units, bacitracin zinc 400 Units, hydrocortisone acetate 1%; per g; oph oint.
Indications for NEO-POLYCIN HC:
Ocular inflammation associated with infection.
Apply in the affected eye every 3–4 hours; max 8g per therapeutic course.
Ocular fungal, viral or mycobacterial infections.
Do not inject into the eye. Corneal or scleral thinning. Glaucoma. Monitor IOP, and for secondary infections in prolonged use. Discontinue if sensitization reaction occurs. Reevaluate if no improvements after 2 days. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antibiotics + steroid.
Local irritation, sensitization (itching, swelling, conjunctival erythema), masks infection, delays healing; in prolonged use: increased IOP, cataracts, corneal perforation, optic nerve damage.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|